Company Profile

Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes: • Stable aqueous glucagon for emergency and artificial pancreas use, • Novel insulin formulations to deliver ultra-rapid acting insulin analogs and; • Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices, and • A series of undisclosed pre-clinical programmes. In addition, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.